Thursday - May 22, 2025
UT-MD Anderson Cancer Center: AACR - Olaparib and Pembrolizumab Combination Shows Early Promise in Molecularly Selected, Tumor-agnostic Trial
April 28, 2025
HOUSTON, Texas, April 28 -- The University of Texas MD Anderson Cancer Center issued the following news release:

* * *

AACR: Olaparib and pembrolizumab combination shows early promise in molecularly selected, tumor-agnostic trial

* Combining Lynparza (olaparib) and Keytruda (pembrolizumab) showed antitumor activity in multiple cancer types, particularly those with BRCA1/2 mutations

* In this combination trial patients were matched by genetic f . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products